{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:10:34Z","timestamp":1768896634315,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40744-023-00589-3","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T12:02:39Z","timestamp":1694433759000},"page":"1503-1518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04758117","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6566-3740","authenticated-orcid":false,"given":"Stephanie G.","family":"Werner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Reckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bohl-B\u00fchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-1331","authenticated-orcid":false,"given":"Marie-Claude","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Jeromin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Baschuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-2731","authenticated-orcid":false,"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6454-1234","authenticated-orcid":false,"given":"Axel J.","family":"Hueber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"589_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jaut.2016.10.009","volume":"76","author":"SP Raychaudhuri","year":"2017","unstructured":"Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun. 2017;76:21\u201337.","journal-title":"J Autoimmun"},{"issue":"4","key":"589_CR2","first-page":"254","volume":"44","author":"J Rodrigues","year":"2019","unstructured":"Rodrigues J, Rodrigues AM, Dias SS, Sousa RD, Branco JC, Canh\u00e3o H. Psoriatic arthritis and ankylosing spondylitis impact on health-related quality of life and working life: a comparative population-based study. Acta Reumatol Port. 2019;44(4):254\u201365.","journal-title":"Acta Reumatol Port"},{"issue":"Suppl 11","key":"589_CR3","first-page":"S64","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res Hoboken. 2011;63(Suppl 11):S64\u201385.","journal-title":"Arthritis Care Res Hoboken"},{"issue":"1","key":"589_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med. 2017;17(1):65\u201370.","journal-title":"Clin Med"},{"issue":"6","key":"589_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"589_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/acr2.11196","volume":"2","author":"AM Liphardt","year":"2020","unstructured":"Liphardt AM, Manger E, Liehr S, et al. Similar impact of psoriatic arthritis and rheumatoid arthritis on objective and subjective parameters of hand function. ACR Open Rheumatol. 2020;2(12):734\u201340.","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"589_CR7","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"589_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"589_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"589_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol Hoboken NJ. 2019;71(1):5\u201332.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"5","key":"589_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/rheumatology\/keab740","volume":"61","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Szekanecz Z, McGonagle D, et al. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology (Oxford). 2022;61(5):1783\u201394.","journal-title":"Rheumatology (Oxford)"},{"key":"589_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","volume":"67","author":"GE Fragoulis","year":"2016","unstructured":"Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med. 2016;67:337\u201353.","journal-title":"Annu Rev Med"},{"issue":"2","key":"589_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/rheumatology\/key070","volume":"58","author":"DJ Veale","year":"2019","unstructured":"Veale DJ, McGonagle D, McInnes IB, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2019;58(2):197\u2013205.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"589_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001838","volume":"7","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e001838.","journal-title":"RMD Open"},{"key":"589_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00499-w","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Kato K, Magrey M, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther. 2022. https:\/\/doi.org\/10.1007\/s40744-022-00499-w.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"589_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80(3):312\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"589_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database. JAMA Dermatol. 2022;158(5):513\u201322.","journal-title":"JAMA Dermatol"},{"issue":"Suppl 1","key":"589_CR18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2022-eular.1606","volume":"81","author":"D Choquette","year":"2022","unstructured":"Choquette D, Chandran V, Lalibert\u00e9 MC, et al. AB0895 Residual burden and disease activity of Canadian PsA patients treated with advanced therapies: preliminary results from a multiple registry analysis (UNISON-PsA). Ann Rheum Dis. 2022;81(Suppl 1):1575\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"589_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729\u201340.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"589_CR20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/j.1365-2133.2007.08183.x","volume":"157","author":"CL Thomas","year":"2007","unstructured":"Thomas CL, Finlay AY. The \u2018handprint\u2019 approximates to 1% of the total body surface area whereas the \u2018palm minus the fingers\u2019 does not. Br J Dermatol. 2007;157(5):1080\u20131.","journal-title":"Br J Dermatol"},{"issue":"5","key":"589_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686\u201391.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"589_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"589_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"589_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3899\/jrheum.150826","volume":"43","author":"LC Coates","year":"2016","unstructured":"Coates LC, Helliwell PS. Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol. 2016;43(2):371\u20135.","journal-title":"J Rheumatol"},{"issue":"12","key":"589_CR25","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"5","key":"589_CR26","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9(5):789\u201393.","journal-title":"J Rheumatol"},{"issue":"3","key":"589_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"589_CR28","unstructured":"SAS Institute. SAS\u00ae Version 94. SAS Institute, Cary"},{"issue":"4","key":"589_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jbspin.2013.01.003","volume":"80","author":"M Godfrin-Valnet","year":"2013","unstructured":"Godfrin-Valnet M, Prati C, Puyraveau M, Toussirot E, Letho-Gyselink H, Wendling D. Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients. Jt Bone Spine. 2013;80(4):393\u20138.","journal-title":"Jt Bone Spine"},{"issue":"9","key":"589_CR30","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3899\/jrheum.151244","volume":"43","author":"MJ Kviatkovsky","year":"2016","unstructured":"Kviatkovsky MJ, Ramiro S, Landew\u00e9 R, et al. The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis. J Rheumatol. 2016;43(9):1680\u20136.","journal-title":"J Rheumatol"},{"issue":"1","key":"589_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MKA Basra","year":"2015","unstructured":"Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"issue":"1","key":"589_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13075-018-1739-0","volume":"20","author":"P Helliwell","year":"2018","unstructured":"Helliwell P, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20(1):242.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"589_CR33","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s40744-021-00343-7","volume":"8","author":"E Lubrano","year":"2021","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. The \u2018climb\u2019 towards minimal disease activity in psoriatic arthritis. Rheumatol Ther. 2021;8(3):1443\u201350.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"589_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semarthrit.2011.12.003","volume":"42","author":"SW Dandorfer","year":"2012","unstructured":"Dandorfer SW, Rech J, Manger B, Schett G, Englbrecht M. Differences in the patient\u2019s and the physician\u2019s perspective of disease in psoriatic arthritis. Semin Arthritis Rheum. 2012;42(1):32\u201341.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"589_CR35","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1093\/rheumatology\/keab905","volume":"61","author":"P Nash","year":"2022","unstructured":"Nash P, Richette P, Gossec L, et al. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022;61(8):3257\u201368.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00589-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00589-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00589-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:38:34Z","timestamp":1700152714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00589-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00589-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"28 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Axel J Hueber consultant or speaker: Abbvie, BMS, Eli Lilly, Galapagos, Gilead, Novartis, UCB; Funding for investigator-initiated studies: Novartis. Stephanie G Werner consultant\/honoraria: Abbvie, Janssen-Cilag, Lilly, Pfizer, UCB. Xenofon Baraliakos consultant, speakers bureau, scientific advisory board and honoraria: Abbvie, Amgen, BMS, Chugai, Galapagos, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, UCB. Sabine Reckert participated in non-interventional trials of AbbVie and declares no further conflicts of interest. Martin Bohl-B\u00fchler participated in non-interventional trials of AbbVie GmbH & Co. KG, AMS Advanced Medical Services GmbH, BMS via inVentiv Health Clinical#, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Covance Inc., Galapagos, MSD SHARP & DOHME GMBH, Novartis Pharma GmbH, Pfizer Pharma GmbH, PPD Global Ltd, Rheumatologische Fortbildungsakademie, Roche Pharma AG, Sanofi-Aventis Deutschland GmbH, UCB Biosciences GmbH, Winicker Norimed GmbH and received honoraria for lectures and participation in advisory boards from AbbVie Deutschland GmbH & Co. KG, Amgen GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Galapagos Biopharma Germany GmbH, Gilead Sciences Europe Ltd., GILEAD Sciences GmbH, Hexal AG, Janssen-Cilag GmbH, Lilly Deutschland GmbH, MICE Service GmbH f\u00fcr Mylan Germany Team, MSD SHARP & DOHME GMBH, Novartis Pharma GmbH, Roche Pharma AG, Theramex Germany GmbH, UCB Pharma GmbH. Louis Bessette Speaker: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Lilly, Novartis, Sanofi, Sandoz, Fresenius Kabi, Teva, Organon, JAMP Pharma; Consultant: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Lilly, Novartis, Sanofi, Sandoz, Fresenius Kabi, Teva, Organon, JAMP Pharma; Research: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Gilead, JAMP Pharma. Marie-Claude Lalibert\u00e9, Nikola Baschuk, Katharina Jeromin, Bj\u00f6rn Fritz and Tanya Gerard are employees of AbbVie Corporation and may own AbbVie stocks and\/or options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board approval for the conduct of this study was obtained from the Friedrich-Alexander-University Erlangen-N\u00fcrnberg (# 458_20 B) on 8\u00a0December 2020. The study was performed according to the Declaration of Helsinki and its later amendments. All subjects provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}